key: cord-0963466-4s0kl3yw
authors: Giulia, Rozzo; Alice, Ramondetta; Teresa, Fierro Maria; Paolo, Dapavo; Simone, Ribero
title: Moderate to severe hidradenitis suppurativa under systemic therapy during the COVID‐19 outbreak
date: 2020-05-24
journal: Dermatol Ther
DOI: 10.1111/dth.13680
sha: 5e28b3eb1226705658c39b5d59f751a2209a6176
doc_id: 963466
cord_uid: 4s0kl3yw

nan

The "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2) has spread over the four continents, causing the respiratory manifestations of Coronavirus disease-19 (COVID-19) and satisfying the epidemiological criteria for a pandemic 1 This article is protected by copyright. All rights reserved.

We contacted all the patients through mail or phone call, who maintained the ongoing therapy at the start of the pandemic.

There were no cases of death from COVID-related disease in our study population or patients hospitalized for COVID-related interstitial pneumonia.

There is uncertainty concerning the outcome of COVID-19 infection in patients with HS treatment who are receiving systemic therapies. Indeed, it is largely debated whether biologics should be interrupted to prevent severe complications of the COVID-19 infection such as interstitial pneumonia 4, 5 .

Although HS patients are generally burdened by metabolic and cardiovascular comorbidities and, above all, treated with antibiotic/immunosuppressive/immunomodulating agents, there were no cases of hospitalization or deaths from COVID-19. No patient has reported any symptoms suggesting COVID-19 infection.

We acknowledge the limitations of this retrospective observational study including the absence of serological or molecular investigations to confirm the absence of contact with COVID-19.

However, the objective of the study was not to investigate the incidence of the COVID-19 infection in patients with HS, but to report the occurrence of hospitalization and death, as indicators of severe outcomes related to the COVID-19 infection in a population at higher risk due to many comorbidities despite the younger age.

Concluding the treatment for HS according to guidelines, it should not be interrupted under the COVID-19. Physicians have to reduce the access of HS patients to hospital as much as possible, favoring telemedicine. This article is protected by copyright. All rights reserved.

Time to use the p-word? Coronavirus enters a dangerous new phase

Coronaviruses and immunosuppressed patients. The facts during the third epidemic

Hidradenitis suppurativa: Current and emerging treatments

Antipsoriatic treatments during COVID-19 outbreak

Should biologics for psoriasis be interrupted in the era of COVID-19?